专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20050085415A1 Methods and compositions for the treatment of eye diseases 审中-公开
标题翻译：用于治疗眼部疾病的方法和组合物
公开(公告)号：US20050085415A1
公开(公告)日：2005-04-21
申请号：US10504431
申请日：2003-02-12
申请人： Matthias Wiesner , Ulrich Lang , Hans Bender , Martin Friedlander
发明人： Matthias Wiesner , Ulrich Lang , Hans Bender , Martin Friedlander
IPC分类号： A61K9/10 , A61K9/00 , A61K9/14 , A61K9/51 , A61K31/353 , A61K31/405 , A61K31/4178 , A61K31/4184 , A61K31/4439 , A61K31/535 , A61K31/538 , A61K38/00 , A61K38/12 , A61K45/00 , A61K47/34 , A61P3/10 , A61P27/02 , A61P27/10 , C07K5/12
CPC分类号： A61K38/12 , A61K9/0048 , A61K9/51 , A61K31/353 , A61K31/405 , A61K31/535 , A61K47/34
摘要： Method and compositions for prophylaxis and/or treatment of diseases of the eye using antagonists of the integin receptors αvβ3 and/or αvβ5. The compositions can be nanoparticles and are administered to the eye by injection into the subTenon's space of the eye.
摘要翻译：使用整合受体α1β3和/或α2β3的拮抗剂预防和/或治疗眼睛疾病的方法和组合物， β5。组合物可以是纳米颗粒，并且通过注射到眼睛的子宫的空间中施用于眼睛。

2. 发明授权

US07645736B2 Integrin inhibitors for the treatment of eye diseases 失效
标题翻译：用于治疗眼部疾病的整合素抑制剂
公开(公告)号：US07645736B2
公开(公告)日：2010-01-12
申请号：US11510596
申请日：2006-08-28
申请人： Hans-Markus Bender , Jutta Haunschild , Ulrich Lang , Matthias Wiesner , Martin Friedlander
发明人： Hans-Markus Bender , Jutta Haunschild , Ulrich Lang , Matthias Wiesner , Martin Friedlander
IPC分类号： A61K38/00
CPC分类号： A61K31/538 , A61K31/335 , A61K31/351 , A61K31/38 , A61K31/395 , A61K31/405 , A61K38/12
摘要： Methods for the treatment of a disease of the eye of a patient comprising injecting into the vitreous body of the eye a composition comprising a therapeutically effective amount of an αvβ3 and/or αvβ5 inhibitor sufficient to inhibit angiogenesis and inhibit neovascularization in the treated eye. The αvβ3 and/or αvβ5 inhibitor being a compound of formula II: as defined herein or a physiologically acceptable salt thereof.
摘要翻译：用于治疗患者眼睛疾病的方法，包括将眼睛的玻璃体注入含有治疗有效量的足以抑制血管发生并抑制治疗眼睛新生血管形成的α噬菌体3和/或甲泼尼布5抑制剂的组合物。阿尔法派菌素3和/或阿尔泊肽5抑制剂是式II化合物：如本文所定义或其生理上可接受的盐。

3. 发明申请

US20060287225A1 Integrin inhibitors for the treatment of eye diseases 失效
标题翻译：用于治疗眼部疾病的整合素抑制剂
公开(公告)号：US20060287225A1
公开(公告)日：2006-12-21
申请号：US11510596
申请日：2006-08-28
申请人： Hans-Markus Bender , Jutta Haunschild , Ulrich Lang , Matthias Wiesner , Martin Friedlander
发明人： Hans-Markus Bender , Jutta Haunschild , Ulrich Lang , Matthias Wiesner , Martin Friedlander
IPC分类号： A61K38/12 , A61K31/5415 , A61K31/538 , A61K31/498 , A61K31/4178 , A61K31/353
CPC分类号： A61K31/538 , A61K31/335 , A61K31/351 , A61K31/38 , A61K31/395 , A61K31/405 , A61K38/12
摘要： Methods and compositions for prophylaxis and/or treatment of diseases of the eye using antagonists of the integin receptors αvβ3 and/or αvβ5. The compositions can be nanoparticles and are administered to the eye by injection into the vitreous body of the eye.
摘要翻译：使用整合受体α1β3和/或α2β3的拮抗剂预防和/或治疗眼睛疾病的方法和组合物 β5。组合物可以是纳米颗粒，并通过注射到眼睛的玻璃体中施用于眼睛。

4. 发明授权

US07648959B2 Methods and compositions for the treatment of diseases of the eye 失效
标题翻译：用于治疗眼睛疾病的方法和组合物
公开(公告)号：US07648959B2
公开(公告)日：2010-01-19
申请号：US11448001
申请日：2006-06-07
申请人： Hans-Markus Bender , Jutta Haunschild , Matthias Wiesner , Ulrich Lang , Martin Friedlander
发明人： Hans-Markus Bender , Jutta Haunschild , Matthias Wiesner , Ulrich Lang , Martin Friedlander
IPC分类号： A61K38/00
CPC分类号： A61K9/5138 , A61K9/0048 , A61K31/352 , A61K31/357 , A61K31/405 , A61K31/41 , A61K31/4184 , A61K31/44 , A61K31/536 , A61K38/12
摘要： Methods and compositions for prophylaxis and/or treatment of diseases of the eye of a patient resulting angiogenesis in the eye using antagonists of the integrin receptors αv β3 and/or αv β5. The compositions can be nanoparticles and are administered to the eye by injection into the sclera of the eye.
摘要翻译：用于预防和/或治疗患者眼睛疾病的方法和组合物，其使用整合素受体α1β和/或α1β5的拮抗剂在眼睛中产生血管生成。组合物可以是纳米颗粒，并通过注射到眼睛的巩膜中施用于眼睛。

5. 发明申请

US20060223746A1 Methods and compositions for the treatment of diseases of the eye 失效
标题翻译：用于治疗眼睛疾病的方法和组合物
公开(公告)号：US20060223746A1
公开(公告)日：2006-10-05
申请号：US11448001
申请日：2006-06-07
申请人： Hans-Markus Bender , Jutta Haunschild , Matthias Wiesner , Ulrich Lang , Martin Friedlander
发明人： Hans-Markus Bender , Jutta Haunschild , Matthias Wiesner , Ulrich Lang , Martin Friedlander
IPC分类号： A61K38/12
CPC分类号： A61K9/5138 , A61K9/0048 , A61K31/352 , A61K31/357 , A61K31/405 , A61K31/41 , A61K31/4184 , A61K31/44 , A61K31/536 , A61K38/12
摘要： Methods and compositions for prophylaxis and/or treatment of diseases of the eye of a patient resulting angiogenesis in the eye using antagonists of the integrin receptors αvβ3 and/or αvβ5. The compositions can be nanoparticles and are administered to the eye by injection into the sclera of the eye.
摘要翻译：使用整联蛋白受体α3β3和/或α的拮抗剂预防和/或治疗患者眼睛疾病的血液发生的方法和组合物 5＆lt; 5＆gt;＆lt; 5＆gt;。组合物可以是纳米颗粒，并通过注射到眼睛的巩膜中施用于眼睛。

6. 发明授权

US07931891B2 Isolated myeloid-like bone marrow cell populations and methods of treatment therewith 失效
标题翻译：分离的骨髓样骨髓细胞群体及其治疗方法
公开(公告)号：US07931891B2
公开(公告)日：2011-04-26
申请号：US11884958
申请日：2006-02-24
申请人： Martin Friedlander , Matthew R. Ritter , Stacey K. Moreno
发明人： Martin Friedlander , Matthew R. Ritter , Stacey K. Moreno
IPC分类号： A01N65/00 , A01N1/02 , A01K48/00
CPC分类号： C12N5/0647 , A61K2035/124 , C12N5/0692
摘要： The present invention provides an isolated myeloid-like cell population comprising a majority of cells that are lineage negative, and which express both CD44 antigen, CD11b antigen, and hypoxia inducible factor 1 α (HIF-1 α). These cells have beneficial vasculotrophic and neurotrophic activity when intraocularly administered to the eye of a mammal, particularly a mammal suffering from an ocular degenerative disease. The myeloid-like cells are isolated by treating bone marrow cells, peripheral blood cells or umbilical cord cells with an antibody against CD44 (hyaluronic acid receptor), against CD11b, CD14, CD33, or against a combination thereof and using flow cytometry to positively select CD44 and/or CD11b expressing cells therefrom. The isolated myeloid-like bone marrow cells of the invention can be transfected with a gene encoding a therapeutically useful protein, for delivering the gene to the retina.
摘要翻译：本发明提供了分离的骨髓样细胞群，其包含谱系阴性的大部分细胞，并表达CD44抗原，CD11b抗原和缺氧诱导因子1α（HIF-1α）。当眼内施用于哺乳动物，特别是患有眼变性疾病的哺乳动物的眼睛时，这些细胞具有有益的血管营养和神经营养活性。通过用针对CD44（透明质酸受体）的抗体对CD11b，CD14，CD33或其组合处理骨髓细胞，外周血细胞或脐带细胞来分离骨髓样细胞，并使用流式细胞术积极选择 CD44和/或CD11b表达细胞。本发明的分离的骨髓样骨髓细胞可以用编码治疗有用的蛋白质的基因转染，用于将该基因递送至视网膜。

7. 发明申请

US20070116685A1 Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith 审中-公开
标题翻译：造血干细胞及其治疗新生血管性眼病的方法
公开(公告)号：US20070116685A1
公开(公告)日：2007-05-24
申请号：US11643571
申请日：2006-12-20
申请人： Martin Friedlander , Atsushi Otani , Karen Silva
发明人： Martin Friedlander , Atsushi Otani , Karen Silva
IPC分类号： A61K35/14 , C12N5/06 , C12N5/08
CPC分类号： C12N5/0692 , A61K48/00 , A61K2035/124 , C12N5/0647
摘要： Isolated, mammalian, bone marrow-derived, hematopoietic stem cell populations contain endothelial progenitor cells (EPC) capable of forming retinal blood vessels. At least about 50% of the cells in the isolated cell population express CD31 and c-kit. Up to about 8% of the cells can express Sca-1, and up to about 4% of the cells can express Flk-1/KDR. The cells can incorporate into the vasculature of the retina when intravitreally injected into the eye, and can thereby stabilize or rebuilt diseased or abnormal retinal blood vessels.
摘要翻译：分离的，哺乳动物，骨髓来源的造血干细胞群含有能够形成视网膜血管的内皮祖细胞（EPC）。分离的细胞群中至少约50％的细胞表达CD31和c-kit。高达约8％的细胞可以表达Sca-1，最多约4％的细胞可以表达Flk-1 / KDR。当玻璃体内注射到眼睛中时，细胞可以并入视网膜的脉管系统中，从而可以稳定或重建患病或异常的视网膜血管。

8. 发明申请

US20060165703A1 Methods and compositions useful for inhibition of alpha v beta 5 mediated angiogenesis 审中-公开
标题翻译：用于抑制αvβ5介导的血管生成的方法和组合物
公开(公告)号：US20060165703A1
公开(公告)日：2006-07-27
申请号：US11290896
申请日：2005-11-29
申请人： Peter Brooks , David Cheresh , Martin Friedlander
发明人： Peter Brooks , David Cheresh , Martin Friedlander
IPC分类号： A61K39/395 , A61K39/00 , C07K14/82 , C07K16/30
CPC分类号： A61K38/57 , A61K2039/505 , C07K16/2839 , C07K16/2848 , C07K2317/76
摘要： The present invention describes methods for inhibiting angiogenesis in tissues using vitronectin αvβ5 antagonists. The αvβ5-mediated angiogenesis is correlated with exposure to cytokines including vascular endothelial growth factor, transforming growth factor-α and epidermal growth factor. Inhibition of αvβ5-mediated angiogenesis is particularly preferred in vascular endothelial ocular neovascular diseases, in tumor growth and in inflammatory conditions, using therapeutic compositions containing αvβ5 antagonists.
摘要翻译：本发明描述了使用玻连蛋白α5β5拮抗剂抑制组织中血管生成的方法。 α-β5介导的血管发生与包括血管内皮生长因子，转化生长因子-α和表皮生长因子在内的细胞因子的暴露相关。使用含有αV的治疗组合物，在血管内皮细胞新生血管疾病，肿瘤生长和炎性病症中，对α5β5介导的血管生成的抑制是特别优选的 5β拮抗剂。

9. 发明申请

US20060104963A1 Treatment of cone cell degeneration with transfected lineage negative hematopoietic stem cells 审中-公开
标题翻译：用转染谱系阴性造血干细胞治疗锥细胞变性
公开(公告)号：US20060104963A1
公开(公告)日：2006-05-18
申请号：US11168130
申请日：2005-06-28
申请人： Martin Friedlander , Atsushi Otani , Karen Silva , Stacey Moreno
发明人： Martin Friedlander , Atsushi Otani , Karen Silva , Stacey Moreno
IPC分类号： A61K48/00 , C12N5/06 , C12N5/08
CPC分类号： C12N5/0647 , A61K38/00 , A61K48/00 , A61K2035/124 , C12N5/0692
摘要： Transfected, mammalian, adult bone marrow-derived, lineage negative hematopoietic stem cell populations (Lin− HSCs) contain endothelial progenitor cells (EPCs) capable of rescuing retinal blood vessels and neuronal networks in the eye. Preferably at least about 20% of the cells express the cell surface antigen CD31. The transfected stem cells express an antiangiogenic fragment of tryptophanyl tRNA synthetase (TrpRS). The transfected Lin− HSC populations are useful for treatment of ocular vascular diseases and to ameliorate cone cell degeneration in the retina. In a preferred embodiment, the Lin− HSCs are isolated by extracting bone marrow from an adult mammal; separating a plurality of monocytes from the bone marrow; labeling the monocytes with biotin-conjugated lineage panel antibodies to one or more lineage surface antigens; removing of monocytes that are positive for the lineage surface antigens from the plurality of monocytes, and recovering a Lin− HSC population containing EPCs. The treatment may be enhanced by stimulating proliferation of activated astrocytes in the retina using a laser.
摘要翻译：转染的哺乳动物，成年骨髓来源的血清造血干细胞群体（含有HSCs）含有能够拯救眼睛中视网膜血管和神经元网络的内皮祖细胞（EPCs）。优选地，至少约20％的细胞表达细胞表面抗原CD31。转染的干细胞表达色氨酸tRNA合成酶（TrpRS）的抗血管生成片段。转染的HSH-HSC群体可用于治疗眼血管疾病并改善视网膜中的锥细胞变性。在一个优选实施方案中，通过从成年哺乳动物中提取骨髓来分离骨髓间充质干细胞; 从骨髓中分离多个单核细胞; 用与生物素缀合的谱系抗体对一种或多种谱系表面抗原标记单核细胞; 从多个单核细胞中除去对于谱系表面抗原呈阳性的单核细胞，以及回收含有EPCs的LINC-HSC群体。可以通过使用激光刺激视网膜中活化的星形胶质细胞的增殖来增强治疗。

10. 发明申请

US20060003933A1 Compositions and methods for treatment of neovascular diseases 失效
公开(公告)号：US20060003933A1
公开(公告)日：2006-01-05
申请号：US11145587
申请日：2005-06-06
申请人： Martin Friedlander , Hilda Aguilar , Michael Dorrell
发明人： Martin Friedlander , Hilda Aguilar , Michael Dorrell
IPC分类号： A61K38/47 , A61K31/7072 , A61K31/538
CPC分类号： A61K31/7072 , A61K9/0048 , A61K31/538 , A61K38/00 , A61K45/06 , C12N9/93 , C12Y601/01002 , A61K2300/00
摘要： The present invention provides compositions and methods of treating neovascular diseases, such as a retinal neovascular diseases and tumors, by administering to a patient suffering from a neovascular disease or tumor a vascular development inhibiting amount of a combination of the angiogenesis suppressing drugs comprising an angiostatic fragment of tryptophanyl-tRNA synthetase (TrpRS) and at least one compound selected from the group consisting of a vascular endothelial growth factor (VEGF) signaling inhibitor and an integrin signaling inhibitor. Compositions for use in the methods include an admixture of an angiostatic fragment of tryptophanyl-tRNA synthetase (TrpRS) and at least one of a vascular endothelial growth factor (VEGF) signaling inhibitor and an integrin signaling inhibitor, together with a pharmaceutically acceptable excipient.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式